Elasmogen

BBI Programme: Regional Angels
Delivery partner: Deepbridge Capital

Part of a cluster of biotech companies in Aberdeen, Elasmogen uses its bespoke technology platform to isolate innovative drugs for treating cancers and auto-immune diseases.

With a strong foundation of intellectual property and a healthy pipeline of new programmes, Elasmogen had progressed several innovative drugs to the late pre-clinical stage. Finance is vital at this early research and development stage.

Funding from Regional Angels Programme delivery partner Deepbridge has added value to the company’s platform, processes and products – and helped to retain its talented team. Elasmogen is now in a position to consider its next major milestone: entering clinical trials.

“ It has transformed our ability to demonstrate the advantages of our technology over the competition.”

Caroline Barelle, CEO